Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…
Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022
The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ: SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.
With New Growth Avenues, Analysts Boost Price Targets For This Botox Competitor
A major overhang has been lifted with the FDA approval of Revance Therapeutics Inc’s (NASDAQ:RVNC) Daxxify (DaxibotulinumtoxinA-lanm). The catalyst also provides a…
Immunocore Shares Fall After Early Solid Cancer Trial Data Of TCR Therapy
Immunocore Holdings plc (NASDAQ:IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well…
AstraZeneca-Merck’s Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
AstraZeneca plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK) announced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line…
‘Executive Order: Declaring A Disaster In The State Of New York’
https://www.governor.ny.gov/executive-order/no-21-declaring-disaster-state-new-york
E X E C U T I V E O R D E R
DECLARING A DISASTER IN THE
‘U.S. Clinical Trial Evaluating Antiviral For Monkeypox Begins, NIH Trial Gathering Data On Tecovirimat (TPOXX)’ – National Institute Of Allergy And Infectious Diseases
https://www.niaid.nih.gov/news-events/us-clinical-trial-evaluating-antiviral-monkeypox-begins
There’s ‘Outsized’ Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with an Overweight (previously Underweight) rating and a price target of $57 from…
‘Highly Compelling’ Eye Drug Data Has Wall Street Stampeding To Buy This ‘Large Cap Growth Story.’ Even After $15B In Market Cap Was Added
Morgan Stanley upgraded Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) to Overweight from Equal Weight with a price target of $851, up from $625. The analyst…
